

# United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

<https://marketpublishers.com/r/U4777F65D9EEN.html>

Date: August 2017

Pages: 107

Price: US\$ 3,800.00 (Single User License)

ID: U4777F65D9EEN

## Abstracts

In this report, the United States Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs in these regions, from 2012 to 2022 (forecast).

United States Pulmonary Arterial Hypertension (PAH) Drugs market competition by top manufacturers/players, with Pulmonary Arterial Hypertension (PAH) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player;

the top players including

Actelion Pharmaceuticals

DAIICHI SANKYO

GlaxoSmithKline

Novartis

United Therapeutics

AADi

Actelion Pharmaceuticals

Aires Pharmaceuticals

Arena Pharmaceuticals

Asklepion Pharmaceuticals

AstraZeneca

Bayer Healthcare

Berlin Cures

BIAL

Eiger BioPharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Inhalation

Injectables

Oral administration

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for each application, including

ERAs

Prostacyclin analogs

PDE inhibitors

sGC stimulators

## Contents

### United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

## 1 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS OVERVIEW

### 1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Drugs

### 1.2 Classification of Pulmonary Arterial Hypertension (PAH) Drugs by Product Category

#### 1.2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)

#### 1.2.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016

##### 1.2.3 Inhalation

##### 1.2.4 Injectables

##### 1.2.5 Oral administration

### 1.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Market by Application/End Users

#### 1.3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)

##### 1.3.2 ERAs

##### 1.3.3 Prostacyclin analogs

##### 1.3.4 PDE inhibitors

##### 1.3.5 sGC stimulators

### 1.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Market by Region

#### 1.4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Value) Comparison by Region (2012-2022)

#### 1.4.2 The West Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)

#### 1.4.3 Southwest Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)

#### 1.4.4 The Middle Atlantic Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)

#### 1.4.5 New England Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)

#### 1.4.6 The South Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)

#### 1.4.7 The Midwest Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)

### 1.5 United States Market Size (Value and Volume) of Pulmonary Arterial Hypertension

(PAH) Drugs (2012-2022)

1.5.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2022)

1.5.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2022)

## **2 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS**

2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Average Price by Players/Suppliers (2012-2017)

2.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Situation and Trends

2.4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Rate

2.4.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Sales Area, Product Type

## **3 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)**

3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Region (2012-2017)

3.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Region (2012-2017)

3.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Region (2012-2017)

## **4 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)**

4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2012-2017)

4.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Type (2012-2017)

## **5 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)**

5.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

## **6 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA**

6.1 Actelion Pharmaceuticals

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 DAIICHI SANKYO

6.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 GlaxoSmithKline

### 6.3.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.3.2.1 Product A

#### 6.3.2.2 Product B

### 6.3.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.3.4 Main Business/Business Overview

## 6.4 Novartis

### 6.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.4.2.1 Product A

#### 6.4.2.2 Product B

### 6.4.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.4.4 Main Business/Business Overview

## 6.5 United Therapeutics

### 6.5.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.5.2.1 Product A

#### 6.5.2.2 Product B

### 6.5.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.5.4 Main Business/Business Overview

## 6.6 AADi

### 6.6.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.6.2.1 Product A

#### 6.6.2.2 Product B

### 6.6.3 AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.6.4 Main Business/Business Overview

## 6.7 Actelion Pharmaceuticals

### 6.7.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.7.2.1 Product A

#### 6.7.2.2 Product B

### 6.7.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.7.4 Main Business/Business Overview

## 6.8 Aires Pharmaceuticals

### 6.8.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.8.2.1 Product A

#### 6.8.2.2 Product B

### 6.8.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.8.4 Main Business/Business Overview

## 6.9 Arena Pharmaceuticals

### 6.9.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.9.2.1 Product A

#### 6.9.2.2 Product B

### 6.9.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.9.4 Main Business/Business Overview

## 6.10 Asklepiion Pharmaceuticals

### 6.10.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification

#### 6.10.2.1 Product A

#### 6.10.2.2 Product B

### 6.10.3 Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.10.4 Main Business/Business Overview

## 6.11 AstraZeneca

## 6.12 Bayer Healthcare

## 6.13 Berlin Cures

## 6.14 BIAL

## 6.15 Eiger BioPharmaceuticals

## **7 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MANUFACTURING COST ANALYSIS**

### 7.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials Analysis

#### 7.1.1 Key Raw Materials

#### 7.1.2 Price Trend of Key Raw Materials

#### 7.1.3 Key Suppliers of Raw Materials

#### 7.1.4 Market Concentration Rate of Raw Materials

### 7.2 Proportion of Manufacturing Cost Structure



7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs

## **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

8.1 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Manufacturers in 2016

8.4 Downstream Buyers

## **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

## **10 MARKET EFFECT FACTORS ANALYSIS**

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

## **11 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)**

11.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume, Revenue Forecast (2017-2022)

11.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume

Forecast by Type (2017-2022)

11.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume

Forecast by Application (2017-2022)

11.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume

Forecast by Region (2017-2022)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 APPENDIX**

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Product Picture of Pulmonary Arterial Hypertension (PAH) Drugs
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (K Units) by Type (2012-2022)
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
- Figure Inhalation Product Picture
- Figure Injectables Product Picture
- Figure Oral administration Product Picture
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (K Units) by Application (2012-2022)
- Figure United States Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application in 2016
- Figure ERAs Examples
- Figure Prostacyclin analogs Examples
- Figure PDE inhibitors Examples
- Figure sGC stimulators Examples
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Million USD) by Region (2012-2022)
- Figure The West Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Southwest Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure The Middle Atlantic Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure New England Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure The South of US Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure The Midwest Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2022)
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Major

Players Product Sales Volume (K Units) (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players/Suppliers

Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players/Suppliers

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players/Suppliers

Table United States Market Pulmonary Arterial Hypertension (PAH) Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)

Figure United States Market Pulmonary Arterial Hypertension (PAH) Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 3 Players/Suppliers

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Drugs Product Category

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Region (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region in 2016

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region in 2016

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) by Region (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2016

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2012-2017)

Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type in 2016

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) by Types (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Type (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Application (2012-2017)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2016

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate

by Application (2012-2017)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Application (2012-2017)

Table Actelion Pharmaceuticals Basic Information List

Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table DAIICHI SANKYO Basic Information List

Table DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table GlaxoSmithKline Basic Information List

Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table Novartis Basic Information List

Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table United Therapeutics Basic Information List

Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table AADi Basic Information List

Table AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table Actelion Pharmaceuticals Basic Information List

Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table Aires Pharmaceuticals Basic Information List

Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table Arena Pharmaceuticals Basic Information List

Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table Asklepiion Pharmaceuticals Basic Information List

Table Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)

Figure Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)

Figure Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)

Table AstraZeneca Basic Information List

Table Bayer Healthcare Basic Information List

Table Berlin Cures Basic Information List

Table BIAL Basic Information List

Table Eiger BioPharmaceuticals Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Drugs

Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs

Figure Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis

Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Players/Suppliers in 2016

Table Major Buyers of Pulmonary Arterial Hypertension (PAH) Drugs

Table Distributors/Traders List

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) Trend Forecast (2017-2022)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Type (2017-2022)



Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Type (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Type in 2022

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Application (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Application (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Application in 2022

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Region (2017-2022)

Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/U4777F65D9EEN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U4777F65D9EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970